The Psoriasis Foundation’s seed grant program emphasizes innovative psoriasis or psoriatic arthritis research projects in genetics, immunology or clinical research focused on understanding the mechanism of the disease.
Genentech has requested priority review on the submission, which means that if accepted, the FDA should take action on the application within six months or in October 2006.
The newly created biopharmaceutical company will trade under the name Infinity Pharmaceuticals and will have a lead product candidate in multiple phase I clinical trials, a second product
The collaboration is specifically targeting viral organisms, including hemorrhagic fever viruses, which pose a serious biological threat to the military and public health of the US. “USAMRIID is
In exchange for receiving this exclusive licence, Viropro will pay about $1 million in the form of 3,500,000 shares. The new deal reinforces the existing agreement signed between
Results of the phase III clinical trial of tramadol (MDT3-005) will be added to the company’s new drug application (NDA), which is currently under FDA review. The randomized,
The heart trial, nicknamed ‘Ruth’, evaluated the use of Evista (Raloxifene HCl) in a large-scale placebo-controlled study. Currently, Evista is not approved by the FDA for preventing or
After a protracted bidding war with Johnson & Johnson, Boston Scientific and Guidant announced that they had entered into a merger agreement on January 25, 2006. Under the
SinuNase is an intranasal Amphotericin B formulation, which the company believes is the first and only drug candidate for chronic sinusitis (CS) to receive fast track status. By
The collaboration was initially formed in February of 2005 to create the commercial line for the first Medarex antibody using the Biolex Lex System. The expansion of the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.